Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 182 | 2025 | 3169 | 14.510 |
Why?
|
Kidney Neoplasms | 170 | 2025 | 4262 | 12.670 |
Why?
|
Interleukin-2 | 36 | 2024 | 1896 | 4.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 82 | 2025 | 11865 | 3.770 |
Why?
|
Melanoma | 62 | 2024 | 5690 | 3.520 |
Why?
|
Immunotherapy | 43 | 2023 | 4752 | 2.970 |
Why?
|
Antibodies, Monoclonal | 50 | 2022 | 9245 | 2.710 |
Why?
|
Antineoplastic Agents | 67 | 2024 | 13639 | 2.080 |
Why?
|
Vascular Endothelial Growth Factor A | 30 | 2024 | 3504 | 1.620 |
Why?
|
Interferon-alpha | 13 | 2018 | 910 | 1.340 |
Why?
|
Phenylurea Compounds | 19 | 2024 | 536 | 1.320 |
Why?
|
Angiogenesis Inhibitors | 23 | 2022 | 2046 | 1.100 |
Why?
|
Molecular Targeted Therapy | 19 | 2019 | 2822 | 1.100 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 10 | 2024 | 1105 | 1.000 |
Why?
|
Neoplasm Metastasis | 40 | 2019 | 4885 | 0.880 |
Why?
|
Skin Neoplasms | 26 | 2022 | 5824 | 0.870 |
Why?
|
Indoles | 19 | 2019 | 1832 | 0.840 |
Why?
|
Niacinamide | 13 | 2022 | 419 | 0.830 |
Why?
|
Pyrroles | 16 | 2018 | 1119 | 0.800 |
Why?
|
Humans | 253 | 2025 | 765734 | 0.650 |
Why?
|
Protein Kinase Inhibitors | 21 | 2024 | 5693 | 0.650 |
Why?
|
Disease-Free Survival | 30 | 2024 | 6832 | 0.640 |
Why?
|
Treatment Outcome | 76 | 2021 | 65180 | 0.620 |
Why?
|
Quinolines | 6 | 2024 | 769 | 0.620 |
Why?
|
Survival Rate | 24 | 2021 | 12787 | 0.610 |
Why?
|
Survival Analysis | 28 | 2024 | 10069 | 0.610 |
Why?
|
Prognosis | 40 | 2024 | 29899 | 0.590 |
Why?
|
Middle Aged | 133 | 2025 | 222903 | 0.580 |
Why?
|
Neoplasm Staging | 31 | 2024 | 11201 | 0.580 |
Why?
|
Aged | 109 | 2025 | 171050 | 0.570 |
Why?
|
Clinical Trials as Topic | 16 | 2019 | 8038 | 0.560 |
Why?
|
Cytokines | 11 | 2023 | 7424 | 0.540 |
Why?
|
Nephrectomy | 9 | 2024 | 927 | 0.530 |
Why?
|
Tumor Microenvironment | 7 | 2024 | 3948 | 0.520 |
Why?
|
Male | 153 | 2025 | 363585 | 0.520 |
Why?
|
Immunotherapy, Adoptive | 2 | 2024 | 1511 | 0.490 |
Why?
|
Kaplan-Meier Estimate | 24 | 2024 | 6499 | 0.480 |
Why?
|
Sirolimus | 10 | 2018 | 1544 | 0.480 |
Why?
|
Female | 148 | 2025 | 395961 | 0.480 |
Why?
|
Proto-Oncogene Proteins B-raf | 11 | 2019 | 2051 | 0.470 |
Why?
|
Cancer Vaccines | 5 | 2013 | 1044 | 0.460 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 7 | 2024 | 658 | 0.460 |
Why?
|
gp100 Melanoma Antigen | 1 | 2013 | 37 | 0.440 |
Why?
|
CD8-Positive T-Lymphocytes | 8 | 2024 | 4642 | 0.440 |
Why?
|
Dose-Response Relationship, Drug | 18 | 2021 | 10730 | 0.420 |
Why?
|
Aged, 80 and over | 49 | 2024 | 59459 | 0.420 |
Why?
|
Maximum Tolerated Dose | 8 | 2017 | 898 | 0.420 |
Why?
|
Adult | 93 | 2025 | 222974 | 0.420 |
Why?
|
Antigens, Neoplasm | 5 | 2020 | 1998 | 0.420 |
Why?
|
Sulfonamides | 6 | 2021 | 1981 | 0.410 |
Why?
|
Benzenesulfonates | 8 | 2011 | 170 | 0.390 |
Why?
|
Urogenital Neoplasms | 1 | 2013 | 129 | 0.390 |
Why?
|
Neoplasms | 15 | 2024 | 22345 | 0.370 |
Why?
|
Endogenous Retroviruses | 2 | 2023 | 112 | 0.360 |
Why?
|
Follow-Up Studies | 21 | 2023 | 39180 | 0.360 |
Why?
|
Angiopoietin-2 | 3 | 2021 | 187 | 0.360 |
Why?
|
Neovascularization, Pathologic | 8 | 2020 | 2630 | 0.360 |
Why?
|
Pyridines | 11 | 2025 | 2889 | 0.360 |
Why?
|
Indazoles | 4 | 2021 | 303 | 0.320 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2017 | 639 | 0.310 |
Why?
|
Receptors, KIR | 2 | 2020 | 114 | 0.300 |
Why?
|
Anilides | 3 | 2025 | 415 | 0.300 |
Why?
|
Imidazoles | 4 | 2019 | 1163 | 0.280 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2024 | 9368 | 0.260 |
Why?
|
Recombinant Proteins | 10 | 2018 | 6492 | 0.260 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2022 | 8603 | 0.260 |
Why?
|
Salvage Therapy | 3 | 2023 | 1272 | 0.260 |
Why?
|
Drug Administration Schedule | 13 | 2018 | 4850 | 0.250 |
Why?
|
Pyrimidines | 4 | 2021 | 3044 | 0.250 |
Why?
|
Clinical Trials, Phase III as Topic | 7 | 2024 | 878 | 0.240 |
Why?
|
Retreatment | 4 | 2020 | 597 | 0.240 |
Why?
|
Drug Therapy, Combination | 8 | 2020 | 6307 | 0.240 |
Why?
|
Skin Diseases | 1 | 2013 | 1080 | 0.240 |
Why?
|
TOR Serine-Threonine Kinases | 10 | 2020 | 2056 | 0.230 |
Why?
|
Research Design | 5 | 2019 | 6207 | 0.230 |
Why?
|
Adjuvants, Immunologic | 4 | 2024 | 995 | 0.230 |
Why?
|
Randomized Controlled Trials as Topic | 12 | 2024 | 10385 | 0.230 |
Why?
|
Quality of Life | 8 | 2023 | 13462 | 0.220 |
Why?
|
Antibodies, Neoplasm | 2 | 2016 | 282 | 0.220 |
Why?
|
Immunomodulation | 2 | 2018 | 547 | 0.220 |
Why?
|
Carcinoma, Papillary | 1 | 2009 | 782 | 0.210 |
Why?
|
Mutation | 17 | 2021 | 30184 | 0.210 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2014 | 890 | 0.210 |
Why?
|
T-Lymphocytes | 9 | 2020 | 10262 | 0.210 |
Why?
|
Double-Blind Method | 9 | 2024 | 12433 | 0.190 |
Why?
|
Butylamines | 1 | 2021 | 9 | 0.190 |
Why?
|
Immunohistochemistry | 12 | 2019 | 11007 | 0.190 |
Why?
|
Immunoglobulins | 2 | 2023 | 852 | 0.180 |
Why?
|
Quinazolines | 1 | 2007 | 1365 | 0.180 |
Why?
|
Combined Modality Therapy | 7 | 2024 | 8528 | 0.180 |
Why?
|
Aminoquinolines | 1 | 2021 | 102 | 0.180 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2022 | 321 | 0.180 |
Why?
|
Models, Economic | 3 | 2020 | 716 | 0.180 |
Why?
|
Disease Progression | 9 | 2022 | 13614 | 0.170 |
Why?
|
Sarcoma | 2 | 2023 | 1801 | 0.170 |
Why?
|
International Agencies | 1 | 2021 | 239 | 0.170 |
Why?
|
Drug Delivery Systems | 1 | 2011 | 2207 | 0.170 |
Why?
|
Deoxycytidine | 3 | 2015 | 889 | 0.170 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 257 | 0.170 |
Why?
|
5'-Nucleotidase | 1 | 2020 | 160 | 0.160 |
Why?
|
Carbonic Anhydrases | 3 | 2010 | 107 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2024 | 3537 | 0.160 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 209 | 0.150 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 2 | 2023 | 1138 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2012 | 561 | 0.150 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 5388 | 0.150 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 120 | 0.150 |
Why?
|
Infusions, Intravenous | 6 | 2017 | 2229 | 0.150 |
Why?
|
Azetidines | 1 | 2019 | 150 | 0.140 |
Why?
|
Oximes | 1 | 2019 | 305 | 0.140 |
Why?
|
Lung Neoplasms | 5 | 2024 | 13448 | 0.140 |
Why?
|
Interleukin-8 | 1 | 2020 | 700 | 0.140 |
Why?
|
4-1BB Ligand | 1 | 2016 | 28 | 0.140 |
Why?
|
Viral Envelope Proteins | 1 | 2020 | 640 | 0.140 |
Why?
|
Forkhead Transcription Factors | 1 | 2024 | 1624 | 0.140 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2020 | 5336 | 0.140 |
Why?
|
Pyrimidinones | 1 | 2019 | 384 | 0.130 |
Why?
|
Antibodies, Blocking | 1 | 2017 | 249 | 0.130 |
Why?
|
Galectin 1 | 1 | 2017 | 128 | 0.130 |
Why?
|
Drug Synergism | 2 | 2019 | 1749 | 0.130 |
Why?
|
Receptors, CXCR4 | 1 | 2021 | 728 | 0.130 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2022 | 2175 | 0.130 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2018 | 422 | 0.130 |
Why?
|
Heart Diseases | 1 | 2009 | 2820 | 0.130 |
Why?
|
Clinical Protocols | 2 | 2019 | 1441 | 0.120 |
Why?
|
Computer Simulation | 2 | 2020 | 6252 | 0.120 |
Why?
|
Young Adult | 15 | 2021 | 59852 | 0.120 |
Why?
|
Benzimidazoles | 1 | 2021 | 864 | 0.120 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2016 | 355 | 0.120 |
Why?
|
Uveal Neoplasms | 1 | 2018 | 343 | 0.120 |
Why?
|
Gene Expression Profiling | 6 | 2021 | 9522 | 0.120 |
Why?
|
Autoimmune Diseases | 3 | 2019 | 2223 | 0.120 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2018 | 548 | 0.120 |
Why?
|
Soft Tissue Neoplasms | 1 | 2023 | 1163 | 0.110 |
Why?
|
Endpoint Determination | 1 | 2017 | 591 | 0.110 |
Why?
|
Paclitaxel | 3 | 2011 | 1728 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1608 | 0.110 |
Why?
|
Models, Organizational | 1 | 2017 | 549 | 0.110 |
Why?
|
Pyridones | 1 | 2019 | 816 | 0.110 |
Why?
|
Tumor Suppressor Proteins | 3 | 2021 | 2794 | 0.110 |
Why?
|
Receptors, IgG | 1 | 2016 | 559 | 0.110 |
Why?
|
Triazoles | 1 | 2018 | 897 | 0.110 |
Why?
|
Survival | 1 | 2013 | 160 | 0.100 |
Why?
|
Prospective Studies | 13 | 2024 | 54795 | 0.100 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 1669 | 0.100 |
Why?
|
Retrospective Studies | 24 | 2021 | 81457 | 0.100 |
Why?
|
Dacarbazine | 2 | 2008 | 552 | 0.100 |
Why?
|
Interleukin-6 | 1 | 2023 | 3229 | 0.100 |
Why?
|
Death | 1 | 2017 | 686 | 0.100 |
Why?
|
Kidney | 3 | 2017 | 7066 | 0.100 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2019 | 1801 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1084 | 0.100 |
Why?
|
Patient Selection | 3 | 2009 | 4254 | 0.100 |
Why?
|
Chemokine CXCL10 | 3 | 2019 | 310 | 0.100 |
Why?
|
Cardiac Tamponade | 1 | 2013 | 176 | 0.100 |
Why?
|
Tumor Burden | 3 | 2015 | 1884 | 0.100 |
Why?
|
Palliative Care | 2 | 2017 | 3645 | 0.100 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2020 | 618 | 0.100 |
Why?
|
Gene Expression | 2 | 2022 | 7584 | 0.100 |
Why?
|
Fatigue | 4 | 2022 | 1550 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 3 | 2020 | 1118 | 0.090 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 3 | 2021 | 303 | 0.090 |
Why?
|
Databases, Factual | 3 | 2023 | 8062 | 0.090 |
Why?
|
Medical Oncology | 3 | 2020 | 2339 | 0.090 |
Why?
|
Perioperative Care | 1 | 2019 | 1055 | 0.090 |
Why?
|
Immunologic Factors | 2 | 2020 | 1585 | 0.090 |
Why?
|
Hyponatremia | 1 | 2013 | 278 | 0.090 |
Why?
|
Time Factors | 9 | 2021 | 40066 | 0.090 |
Why?
|
Vascular Endothelial Growth Factors | 2 | 2010 | 754 | 0.090 |
Why?
|
Piperidines | 1 | 2019 | 1663 | 0.090 |
Why?
|
Neoadjuvant Therapy | 2 | 2019 | 2895 | 0.080 |
Why?
|
Metabolomics | 1 | 2019 | 1668 | 0.080 |
Why?
|
Sequence Analysis, DNA | 2 | 2018 | 4772 | 0.080 |
Why?
|
Recombinant Fusion Proteins | 1 | 2018 | 3737 | 0.080 |
Why?
|
Neoplasm Proteins | 2 | 2013 | 3593 | 0.080 |
Why?
|
Carboplatin | 2 | 2011 | 789 | 0.080 |
Why?
|
Myeloid Cells | 2 | 2023 | 839 | 0.080 |
Why?
|
Brain Neoplasms | 3 | 2022 | 9071 | 0.080 |
Why?
|
Chromosomes, Human, X | 1 | 2010 | 319 | 0.080 |
Why?
|
Amylases | 2 | 2019 | 171 | 0.080 |
Why?
|
Sodium | 1 | 2013 | 1591 | 0.070 |
Why?
|
Prostatic Neoplasms | 3 | 2024 | 11080 | 0.070 |
Why?
|
Cardiovascular System | 1 | 2015 | 840 | 0.070 |
Why?
|
DNA Mutational Analysis | 2 | 2014 | 4106 | 0.070 |
Why?
|
Lymphocyte Depletion | 1 | 2010 | 605 | 0.070 |
Why?
|
Genetic Association Studies | 2 | 2016 | 2740 | 0.070 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2021 | 455 | 0.070 |
Why?
|
Signal Transduction | 7 | 2021 | 23589 | 0.070 |
Why?
|
Lipase | 2 | 2019 | 320 | 0.070 |
Why?
|
Ligands | 3 | 2022 | 3273 | 0.070 |
Why?
|
Biomedical Research | 1 | 2022 | 3458 | 0.070 |
Why?
|
Injections, Subcutaneous | 2 | 2005 | 682 | 0.060 |
Why?
|
Alanine Transaminase | 2 | 2019 | 608 | 0.060 |
Why?
|
Protein Kinases | 3 | 2007 | 1611 | 0.060 |
Why?
|
Patient Care Team | 1 | 2017 | 2517 | 0.060 |
Why?
|
Karnofsky Performance Status | 2 | 2017 | 163 | 0.060 |
Why?
|
Proportional Hazards Models | 6 | 2017 | 12509 | 0.060 |
Why?
|
Cohort Studies | 7 | 2017 | 41631 | 0.060 |
Why?
|
Interferon-gamma | 4 | 2020 | 3159 | 0.060 |
Why?
|
Translocation, Genetic | 1 | 2010 | 1393 | 0.060 |
Why?
|
Arginase | 1 | 2005 | 81 | 0.060 |
Why?
|
Canada | 2 | 2024 | 2119 | 0.060 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2013 | 2024 | 0.060 |
Why?
|
Cell Movement | 1 | 2016 | 5192 | 0.060 |
Why?
|
Animals | 7 | 2023 | 168731 | 0.060 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2008 | 614 | 0.060 |
Why?
|
Immune Tolerance | 1 | 2013 | 2324 | 0.060 |
Why?
|
Predictive Value of Tests | 5 | 2024 | 15390 | 0.060 |
Why?
|
Nuclear Proteins | 1 | 2018 | 5781 | 0.060 |
Why?
|
Survivors | 1 | 2014 | 2374 | 0.050 |
Why?
|
Capillary Permeability | 1 | 2007 | 767 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-kit | 3 | 2015 | 723 | 0.050 |
Why?
|
Placebos | 1 | 2007 | 1659 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3101 | 0.050 |
Why?
|
Sequence Analysis, RNA | 2 | 2020 | 2036 | 0.050 |
Why?
|
United States | 9 | 2022 | 72898 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3224 | 0.050 |
Why?
|
Transcription Factors | 2 | 2020 | 12123 | 0.050 |
Why?
|
Cost-Benefit Analysis | 3 | 2020 | 5526 | 0.050 |
Why?
|
ROC Curve | 2 | 2024 | 3618 | 0.050 |
Why?
|
Ambulatory Care Facilities | 2 | 2017 | 939 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 2 | 2020 | 2470 | 0.040 |
Why?
|
Genotype | 4 | 2016 | 13024 | 0.040 |
Why?
|
Administration, Oral | 1 | 2008 | 4015 | 0.040 |
Why?
|
Antineoplastic Protocols | 1 | 2020 | 47 | 0.040 |
Why?
|
Antigen Presentation | 2 | 2020 | 1250 | 0.040 |
Why?
|
Antigens, CD | 1 | 2010 | 4020 | 0.040 |
Why?
|
Treatment Failure | 2 | 2020 | 2653 | 0.040 |
Why?
|
Outpatients | 1 | 2007 | 1594 | 0.040 |
Why?
|
Pyrazoles | 1 | 2010 | 2031 | 0.040 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2020 | 225 | 0.040 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 162 | 0.040 |
Why?
|
Spin Labels | 1 | 2020 | 334 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2020 | 370 | 0.040 |
Why?
|
GPI-Linked Proteins | 1 | 2020 | 472 | 0.040 |
Why?
|
Gene Fusion | 1 | 2022 | 356 | 0.040 |
Why?
|
Dendritic Cells | 2 | 2007 | 2746 | 0.040 |
Why?
|
Kynurenine | 1 | 2019 | 142 | 0.040 |
Why?
|
Granzymes | 1 | 2020 | 278 | 0.040 |
Why?
|
Tyrosine | 1 | 2023 | 1427 | 0.040 |
Why?
|
Paresthesia | 1 | 2019 | 159 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 561 | 0.040 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2020 | 533 | 0.040 |
Why?
|
Kidney Failure, Chronic | 1 | 2011 | 2495 | 0.040 |
Why?
|
Adolescent | 5 | 2019 | 88781 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2019 | 416 | 0.040 |
Why?
|
Polyethylene Glycols | 2 | 2018 | 1188 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 702 | 0.040 |
Why?
|
Drug Dosage Calculations | 1 | 2018 | 116 | 0.040 |
Why?
|
Tryptophan | 1 | 2019 | 483 | 0.040 |
Why?
|
Histone Demethylases | 1 | 2020 | 328 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2020 | 36537 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2016 | 16041 | 0.030 |
Why?
|
Up-Regulation | 2 | 2016 | 4136 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 3651 | 0.030 |
Why?
|
Risk Factors | 4 | 2022 | 74831 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2013 | 6546 | 0.030 |
Why?
|
Erythropoietin | 1 | 2021 | 716 | 0.030 |
Why?
|
Urologic Neoplasms | 1 | 2020 | 310 | 0.030 |
Why?
|
Disease Management | 2 | 2019 | 2534 | 0.030 |
Why?
|
Chemokine CXCL9 | 1 | 2016 | 137 | 0.030 |
Why?
|
Pruritus | 1 | 2019 | 378 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2020 | 1440 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 904 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2015 | 70 | 0.030 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2020 | 697 | 0.030 |
Why?
|
Piperazines | 1 | 2006 | 2546 | 0.030 |
Why?
|
Urology | 1 | 2020 | 384 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2020 | 1385 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 994 | 0.030 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2017 | 252 | 0.030 |
Why?
|
Genomics | 2 | 2022 | 5924 | 0.030 |
Why?
|
Drug Approval | 1 | 2022 | 818 | 0.030 |
Why?
|
Proteinuria | 1 | 2018 | 606 | 0.030 |
Why?
|
raf Kinases | 1 | 2015 | 116 | 0.030 |
Why?
|
Genetic Heterogeneity | 1 | 2018 | 735 | 0.030 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2024 | 3110 | 0.030 |
Why?
|
Algorithms | 1 | 2015 | 14061 | 0.030 |
Why?
|
Registries | 2 | 2023 | 8293 | 0.030 |
Why?
|
Chemokine CX3CL1 | 1 | 2014 | 60 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1622 | 0.030 |
Why?
|
Prostate-Specific Antigen | 1 | 2024 | 2462 | 0.030 |
Why?
|
Receptors, Immunologic | 1 | 2020 | 1415 | 0.030 |
Why?
|
Macrophages | 2 | 2021 | 5772 | 0.030 |
Why?
|
Cell Line, Tumor | 3 | 2020 | 17062 | 0.030 |
Why?
|
Tumor Cells, Cultured | 2 | 2016 | 6109 | 0.030 |
Why?
|
Health Plan Implementation | 1 | 2017 | 338 | 0.030 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2016 | 694 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1314 | 0.030 |
Why?
|
Decision Trees | 1 | 2015 | 509 | 0.030 |
Why?
|
Finland | 1 | 2014 | 608 | 0.030 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2020 | 788 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2020 | 1737 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2017 | 621 | 0.030 |
Why?
|
Morpholines | 1 | 2016 | 577 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2018 | 1617 | 0.030 |
Why?
|
Codon | 1 | 2014 | 595 | 0.030 |
Why?
|
Immunity, Humoral | 1 | 2017 | 605 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2019 | 20667 | 0.030 |
Why?
|
Adaptation, Physiological | 1 | 2019 | 1308 | 0.030 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2016 | 1132 | 0.030 |
Why?
|
Italy | 1 | 2014 | 851 | 0.030 |
Why?
|
Gene Deletion | 1 | 2020 | 2666 | 0.030 |
Why?
|
Aminopyridines | 1 | 2016 | 576 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1788 | 0.020 |
Why?
|
Glomerular Filtration Rate | 2 | 2011 | 2233 | 0.020 |
Why?
|
Chemokines | 1 | 2016 | 956 | 0.020 |
Why?
|
DNA-Binding Proteins | 2 | 2020 | 9594 | 0.020 |
Why?
|
Mucous Membrane | 1 | 2015 | 656 | 0.020 |
Why?
|
Asia | 1 | 2013 | 628 | 0.020 |
Why?
|
Fever | 1 | 2019 | 1602 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2017 | 2845 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2020 | 6219 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2017 | 2910 | 0.020 |
Why?
|
Adaptive Immunity | 1 | 2016 | 734 | 0.020 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7424 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2423 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2207 | 0.020 |
Why?
|
Odds Ratio | 2 | 2019 | 9647 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2017 | 961 | 0.020 |
Why?
|
Lymphopenia | 1 | 2013 | 297 | 0.020 |
Why?
|
Mice | 3 | 2023 | 81792 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2014 | 634 | 0.020 |
Why?
|
Risk | 2 | 2018 | 9592 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2016 | 1740 | 0.020 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2015 | 698 | 0.020 |
Why?
|
Hospice Care | 1 | 2017 | 678 | 0.020 |
Why?
|
Myocarditis | 1 | 2018 | 802 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2014 | 1739 | 0.020 |
Why?
|
Compassionate Use Trials | 1 | 2010 | 49 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2016 | 3089 | 0.020 |
Why?
|
Pilot Projects | 3 | 2010 | 8732 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3595 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2017 | 954 | 0.020 |
Why?
|
Hypertension | 2 | 2019 | 8626 | 0.020 |
Why?
|
Computational Biology | 1 | 2020 | 3558 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 3200 | 0.020 |
Why?
|
Lymphocytes | 1 | 2016 | 2600 | 0.020 |
Why?
|
Models, Biological | 2 | 2019 | 9441 | 0.020 |
Why?
|
Phenotype | 2 | 2016 | 16706 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 1856 | 0.020 |
Why?
|
Hypotension | 1 | 2013 | 885 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2005 | 5195 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7599 | 0.020 |
Why?
|
Europe | 1 | 2013 | 3423 | 0.020 |
Why?
|
North America | 1 | 2010 | 1285 | 0.020 |
Why?
|
Digestive System Diseases | 1 | 2007 | 151 | 0.020 |
Why?
|
Cell Membrane | 1 | 2015 | 3633 | 0.020 |
Why?
|
Safety | 1 | 2010 | 1157 | 0.020 |
Why?
|
Skin | 1 | 2019 | 4474 | 0.020 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2006 | 183 | 0.020 |
Why?
|
Ornithine | 1 | 2005 | 79 | 0.020 |
Why?
|
Health Care Costs | 1 | 2018 | 3242 | 0.020 |
Why?
|
Terminal Care | 1 | 2017 | 1774 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2010 | 1325 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2016 | 4352 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2018 | 3818 | 0.010 |
Why?
|
Risk Assessment | 2 | 2017 | 24279 | 0.010 |
Why?
|
Observer Variation | 1 | 2011 | 2611 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2014 | 20120 | 0.010 |
Why?
|
Body Mass Index | 1 | 2022 | 13044 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 2007 | 1696 | 0.010 |
Why?
|
Hybrid Cells | 1 | 2004 | 421 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2016 | 3078 | 0.010 |
Why?
|
Germ-Line Mutation | 1 | 2012 | 1883 | 0.010 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2006 | 367 | 0.010 |
Why?
|
Doxorubicin | 1 | 2011 | 2229 | 0.010 |
Why?
|
Medical Records | 1 | 2009 | 1409 | 0.010 |
Why?
|
Massachusetts | 1 | 2017 | 8876 | 0.010 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2005 | 217 | 0.010 |
Why?
|
Incidence | 1 | 2022 | 21478 | 0.010 |
Why?
|
Electrons | 1 | 2005 | 265 | 0.010 |
Why?
|
CD4 Lymphocyte Count | 1 | 2010 | 2586 | 0.010 |
Why?
|
Vaccination | 2 | 2007 | 3427 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14745 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2008 | 1831 | 0.010 |
Why?
|
Area Under Curve | 1 | 2007 | 1639 | 0.010 |
Why?
|
Hematologic Diseases | 1 | 2007 | 500 | 0.010 |
Why?
|
Exanthema | 1 | 2007 | 500 | 0.010 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2008 | 728 | 0.010 |
Why?
|
Drug Costs | 1 | 2010 | 1193 | 0.010 |
Why?
|
Respiratory Tract Diseases | 1 | 2007 | 744 | 0.010 |
Why?
|
Alleles | 1 | 2012 | 6893 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 3684 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15883 | 0.010 |
Why?
|
Arginine | 1 | 2005 | 933 | 0.010 |
Why?
|
Renal Dialysis | 1 | 2011 | 1799 | 0.010 |
Why?
|
Societies, Medical | 1 | 2013 | 3955 | 0.010 |
Why?
|
Vinblastine | 1 | 2002 | 483 | 0.010 |
Why?
|
Cytoplasm | 1 | 2005 | 1497 | 0.010 |
Why?
|
Interleukin-12 | 1 | 2003 | 579 | 0.010 |
Why?
|
Coculture Techniques | 1 | 2004 | 1336 | 0.010 |
Why?
|
Benzamides | 1 | 2006 | 1376 | 0.010 |
Why?
|
Academic Medical Centers | 1 | 2011 | 2779 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8703 | 0.010 |
Why?
|
Medicare | 1 | 2018 | 6821 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18375 | 0.010 |
Why?
|
Forecasting | 1 | 2009 | 2936 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 3805 | 0.010 |
Why?
|
Obesity | 1 | 2022 | 13079 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2002 | 633 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 14637 | 0.010 |
Why?
|
Cell Separation | 1 | 2004 | 1718 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2007 | 2454 | 0.010 |
Why?
|
Drug Hypersensitivity | 1 | 2007 | 903 | 0.010 |
Why?
|
Boston | 1 | 2011 | 9337 | 0.010 |
Why?
|
Recurrence | 1 | 2010 | 8498 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2004 | 21053 | 0.010 |
Why?
|
Phosphorylation | 1 | 2007 | 8279 | 0.010 |
Why?
|
Cisplatin | 1 | 2002 | 1657 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18289 | 0.010 |
Why?
|
Acute Kidney Injury | 1 | 2007 | 1945 | 0.010 |
Why?
|
Cardiomyopathies | 1 | 2007 | 2067 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2007 | 3584 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2005 | 5501 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2004 | 5879 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 18061 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2008 | 12949 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2012 | 6952 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2007 | 18972 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2004 | 10428 | 0.000 |
Why?
|